Stock Mumak

Stock Profile

Moderna

Moderna strengthens its mRNA platform with positive Phase 3 data in oncology and the approval of MFLUSIVA; however, financial risks remain high.
Moderna
Pharmaceuticals & Biotechnology

Valuation Analysis: Moderna

ISIN: US60770K1079

Moderna is undergoing a transition from a COVID-19 vaccine provider to a broader mRNA biotechnology platform. Positive Phase 3 data for autogene intismeran in melanoma and the FDA approval of MFLUSIVA strengthen the outlook in oncology and respiratory diseases. At the same time, high losses, cash burn, and regulatory risks continue to weigh on the overall outlook.
Compass 4 out of 5
More research

Latest Portfolio Updates

Revolution Medicines
Company Update

European Defense Stocks Under Pressure: How the UMBRELLA Strategy Reacts

European defense stocks are coming under pressure. How does the UMBRELLA Strategy react to weaker momentum, high valuations, and the
Next Update
RED HOT CHILI™ MUMAK

RED HOT CHILI™ MUMAK of the Week: Micron Technology – AI memory in focus

Micron Technology is benefiting from strong demand for AI memory. Fundamentals, the industry backdrop, and technicals are providing positive tailwinds.
Next Update
Weekly Update

Weekly Market Overview – August 31-September 6, 2026

UMBRELLA strategy: Focus continues to shift toward healthcare and advanced technologies
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Eli Lilly and Palantir in focus

Eli Lilly strengthens its pipeline, Palantir remains volatile, and Johnson & Johnson gains momentum. The most important developments of the
Next Update